NAMUR, Belgium, Dec. 1,
2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX)
today announced that it will attend the Citi 2016 Global Healthcare
Conference being held on December 7-8,
2016 at The Lotte New York Palace in New York, NY.
At the Citi Conference, Jake
Micallef, Chief Scientific Officer of Volition, and
Scott Powell, Vice President of
Investor Relations, will provide an update on Volition's business,
clinical, regulatory and operational milestones, as well as the
Company's recently announced product launch of its
Nu.QTM Colorectal Cancer Screening Triage Test.
Volition plans to also attend three more conferences this month
in addition to Citi. The details of such conferences are as
follows:
Event:
|
The Benchmark
Company, LLC Micro Cap Discovery Conference
|
Date:
|
Thursday, December 1,
2016
|
Location:
|
The Palmer House
Hilton Hotel, Chicago, IL
|
|
|
Event:
|
The Nordic-American
Life Science Conference
|
Date:
|
Thursday, December 1,
2016
|
Location:
|
10 on the Park, New
York, NY
|
|
|
Event:
|
LD Micro Main
Event
|
Date:
|
Tuesday – Thursday,
December 6-8, 2016
|
Presentation Time:
|
Tuesday, December
6th, 12:00 pm Pacific Time
|
Location:
|
Luxe Sunset Boulevard
Hotel, Los Angeles, CA
|
Persons attending any of the above-referenced conferences who
would like to schedule a 1-on-1 meeting with Volition management
during such conference may do so by contacting Tirth Patel of Edison Advisors at
tpatel@edisongroup.com or Scott
Powell, Vice President of Investor Relations of Volition, at
S.Powell@volitionrx.com.
About Volition
Volition is a life sciences company focused on developing
diagnostic tests for cancer. The tests are based on the science of
Nucleosomics®, which is the practice of identifying and
measuring nucleosomes in the bloodstream or other bodily fluid – an
indication that disease is present.
Volition's goal is to make the tests as easy and simple to use,
for both patients and doctors, as existing diabetic and cholesterol
blood tests. Volition's research and development activities are
currently centered in Belgium as
the company focuses on bringing its diagnostic products to market
first in Europe, then in the U.S.
and ultimately, worldwide.
For more information about Volition, visit Volition's website
(http://www.volitionrx.com) or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter,
LinkedIn, Facebook, and YouTube are included in this document as
inactive textual references only.
Media / Investor Contacts
Louise Day,
Volition
L.day@volitionrx.com
+44 (0)7557
774620
|
Scott Powell,
Volition
S.powell@volitionrx.com
+1 (646) 650
1351
|
Tirth Patel,
Edison Advisors
tpatel@edisongroup.com
+1 (646) 653
7035
|
Rachel Carroll,
Edison Advisors
rcarroll@edisongroup.com
+44 (0)20 3077
5711
|
Sarah Roberts,
Vane Percy & Roberts
sarah@vanepercy.com
+44 (0)1737 821
890
|
|
Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and
their respective logos are trademarks and/or service marks of
VolitionRx Limited and its subsidiaries. All other trademarks,
service marks and trade names referred to in this press release are
the property of their respective owners.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/volitionrx-limited-to-attend-citi-2016-global-healthcare-conference-300371361.html
SOURCE VolitionRx Ltd